on Esaote S.p.A
Esaote Unveils PAM Technology at EAU 2026 for Enhanced Urological Imaging
At the 41st Annual European Association of Urology Congress in London, Esaote S.p.A introduced its Prostate Attention Map (PAM) technology. This innovation, available on the new MyLab™E85 GTS edition, aims to advance precision in urological imaging. The PAM technology, integrated with Esaote's UroFusion software, offers automatic analysis of prostate mpMRI volumes. It assists urologists in identifying suspicious regions, thus improving target guidance and decision-making processes.
Alongside PAM, Esaote showcased the MyLab™C30 GTS edition. This portable ultrasound system maintains high image quality while meeting varied examination settings. Both systems are part of Esaote's Guided Therapy Solutions line, emphasizing confidence, efficiency, and clinical excellence in prostate care.
Marta Daniel, Guided Therapy Product and Clinical Solutions Manager at Esaote, highlighted the role of A.I. in ensuring a seamless workflow during prostate biopsies. Esaote actively participated in TP Biopsy sessions at the congress, offering hands-on experience with its UroFusion advances.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Esaote S.p.A news